- Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, which results in symptoms ranging from muscle weakness to vision loss and paralysis.
- It generally strikes in early adulthood, and is more common in women than men.
- Several treatments can slow the progression of the disease, meaning that most people do not experience severe disability.
- Now, a new biosimilar injection of a current drug has been approved by the Food and Drug Administration (FDA) in the United States for use in people with relapsing forms of MS.
- The new drug, Tyruko, may mean more cost-effective treatment is available for many people with the condition.
Multiple sclerosis (MS) — a chronic, inflammatory disease of the nervous system — is thought to affect some
Symptoms range from the mild, such as blurred vision, and tingling and numbness in the limbs, to the more severe, including mobility problems, paralysis, and vision loss, although most people with the condition do not experience severe disability.
There are several types of MS. Relapsing-remitting MS, which is characterized by disease flare-ups and periods of remission when there is partial or total recovery, is the most common.
Treatment can slow the progression of the disease but, as this is a lifelong condition, the cost can mount up, particularly for
One treatment used for people who have not responded well to first-line therapies is natalizumab (Tysabri), a monoclonal antibody.
It can slow the progression of…
Read the full article here